Wenjun Chen, Xiaoming Zhou

For correspondence:-  Xiaoming Zhou   Email: zxm666zxm666@126.com   Tel:+86-018718193818

Received: 5 December 2023        Accepted: 10 December 2024        Published: 30 December 2024

Citation: Chen W, Zhou X. Treatment of peripheral neuropathy in type 2 diabetes with epalrestat combined with sulodexide. Trop J Pharm Res 2024; 23(12):2017-2023 doi: 10.4314/tjpr.v23i12.6

© 2024 The authors.
This is an Open Access article that uses a funding model which does not charge readers or their institutions for access and distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0) and the Budapest Open Access Initiative (http://www.budapestopenaccessinitiative.org/read), which permit unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited..

Abstract

Purpose: To analyze the efficacy of epalrestat combined with Sulodexide in the treatment of diabetic peripheral neuropathy in type 2 diabetes. Methods: A total of 140 patients with type 2 diabetic peripheral neuropathy, who were treated at the Zhanjiang Central People's Hospital between February 2022 and February 2023, were selected as subjects. They were randomly divided into two groups using a computer-generated random number table. The control group (n = 70) received epalrestat treatment, while the study group (n = 70) was treated with a combination of epalrestat and Sulodexide11. Efficacy, nerve conduction velocity, levels of inflammatory factors and oxidative stress markers were compared between groups. Results: After treatment, total effective rate in study group was 97.14 %, which was higher than that of control group (85.71 %; p < 0.05). Sensory nerve conduction velocity (SCV) and motor nerve conduction velocity (MCV) of the common peroneal nerve and median nerve in study group were significantly faster than those in control group (p < 0.05). Levels of serum high-sensitivity C-reactive protein (hs-CRP), interleukin-6 (IL-6), procalcitonin (PCT) and tumor necrosis factor-α (TNF-α) in study group were significantly lower than those in control group (p < 0.05). Total antioxidant capacity (T-AOC) and superoxide dismutase (SOD) levels in study group were higher than those in control group, while malondialdehyde (MDA) level was lower than control group (p < 0.05). Conclusions: Epalrestat combined with Sulodexide in treatment of diabetic peripheral neuropathy in type 2 diabetes improves efficacy, accelerates nerve conduction velocity, reduces inflammatory factor levels and decreases oxidative stress response. Further studies are necessary to accurately verify the combination therapy value using epalrestat and Sulodexide in treating peripheral neuropathy associated with type 2 diabetes.